A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration.

Gary C. Brown,Melissa M. Brown,Heidi B. Lieske,Philip A. Lieske,Kathryn S. Brown

A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration.

2015

Gary C. Brown
Melissa M. Brown
Heidi B. Lieske
Philip A. Lieske
Kathryn S. Brown

Background There is a dearth of patient, preference-based cost-effectiveness analyses evaluating genetic testing for neovascular age-related macular degeneration (NVAMD).

Keywords:

Macular degeneration
Genetic testing
Pathology
Cost–utility analysis
Medicine
medical costs
cost effectiveness
Pediatrics
Ranibizumab
Cohort
world health

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations